Burkitt's lymphoma

Burkitt lymphoma is a highly aggressive mature B-cell non-Hodgkin lymphoma and the most rapidly proliferating human cancer.[1] It is of germinal center B-cell origin, genetically defined by translocation of the MYC oncogene, most commonly t(8;14)(q24;q32).[1] In the jaws, it manifests as a rapidly destructive osteolytic process with poorly defined margins, often mimicking odontogenic infection.[2][3] Three epidemiologic variants are recognized—endemic, sporadic, and immunodeficiency-associated—each with distinct patterns of jaw involvement.[1] Treatment is systemic intensive immunochemotherapy; surgical resection is not indicated.[1] The disease is curable in the majority of patients when diagnosed promptly.[1]

Current Classification

Both the WHO Classification of Haematolymphoid Tumours, 5th edition (WHO-HAEM5, 2024) and the International Consensus Classification (ICC, 2022) retain Burkitt lymphoma as a distinct entity within mature B-cell neoplasms.[4]

Accepted Names and Aliases

• Burkitt lymphoma (preferred)
• Burkitt's lymphoma (eponymous variant, widely used)

Obsolete or Historical Terms

• "Small noncleaved cell lymphoma, Burkitt type" (former Working Formulation terminology)
• "African lymphoma" (historical; now subsumed under the endemic variant designation)
• "Undifferentiated lymphoma, Burkitt type"

The term "Burkitt-like lymphoma" is no longer recommended; cases previously so designated are now classified as high-grade B-cell lymphoma, NOS, or other specific entities under WHO-HAEM5/ICC.[5]

• Endemic variant: Occurs in equatorial Africa and Papua New Guinea, where it is the most common pediatric cancer. Incidence is 3–6 per 1,000 children. Jaw and orbital involvement predominate in young children (peak ages 3–7 years), though contemporary data show increasing abdominal presentations. Male-to-female ratio is approximately 2:1. Nearly all cases are EBV-positive.[1]
• Sporadic variant: Accounts for 30–50% of childhood lymphomas and 1–2% of adult lymphomas worldwide. Median age at presentation is 10 years, with additional incidence peaks at 40 and 75 years. Male-to-female ratio is 3–4:1. Jaw involvement is less frequent than in the endemic form; the abdomen (ileocecal region) is the most common site. EBV is associated with 20–30% of cases.[1][6]
• Immunodeficiency-associated variant: Median age 40–45 years; equal sex distribution. Represents approximately 40% of HIV-associated lymphomas. More nodal involvement than other variants.[1][6]

In the jaws specifically, the sporadic variant shows unilateral mandibular involvement as the most common pattern, with maxillary and multiquadrant disease less frequent.[7]

Presentation and Symptoms

Jaw involvement may be the initial manifestation, particularly in the endemic variant and in children.[6][7] Clinical features depend on the variant and patient age:

• Children (endemic): Rapidly progressive facial or periorbital swelling, loose or "floating" teeth, intraoral masses, and cervical lymphadenopathy[6][8]
• Children and adolescents (sporadic): Toothache, loose teeth, intraoral and extraoral swelling[7]
• Adults (sporadic): Toothache and perioral numbness (inferior alveolar nerve involvement) are the most frequent complaints; swelling may be less prominent initially[7]

Tempo and Red Flags

The doubling time is extremely short, and radiographic progression can be documented within days to weeks.[9] Key red flags include:

• Rapid tooth mobility without proportionate periodontal disease
• Neurosensory disturbance (numbness, paresthesia) of the inferior alveolar or infraorbital nerve[2][7]
• Failure of presumed odontogenic infection to respond to appropriate treatment[3][10]
• Bilateral or multiquadrant jaw involvement in a child or young adult

Diagnostic Pitfall

A majority of patients with jaw involvement are initially evaluated by a dentist, and misdiagnosis as periodontitis, periapical abscess, or dentoalveolar infection is common—reported in over half of cases in one series.[7] Unnecessary extractions and antibiotic courses delay definitive diagnosis.

Location and Distribution

• Endemic variant: Maxilla and mandible are both commonly affected; multiquadrant involvement is frequent, and bilateral jaw disease occurs.[6][8]
• Sporadic variant: Unilateral mandibular involvement is the most common pattern (particularly the posterior body and angle region), followed by unilateral maxillary and bilateral mandibular disease. Four-quadrant involvement is uncommon.[7][11]
• Maxillary alveolar lesions tend to present with a shorter duration of symptoms, reflecting aggressive local behavior.[3]

Periphery and Shape

• Margins are characteristically poorly defined and irregular, without a corticated border.[8][12]
• The lesion lacks a sclerotic rim or capsule, consistent with a permeative or moth-eaten pattern of bone destruction.
• Shape is variable and often irregular, conforming to the medullary space rather than producing a discrete geometric outline.

Internal Architecture

• Purely radiolucent (osteolytic) without internal calcification, osteoid, or cartilaginous matrix.[11]
• The normal trabecular architecture is effaced and replaced by a homogeneous radiolucency.
• On panoramic radiographs, the appearance may initially simulate periapical radiolucencies of inflammatory origin, particularly when centered around tooth apices.[3][9]

Effects on Teeth and Adjacent Structures

• Loss of lamina dura is a hallmark finding, reported in over 90% of cases with jaw-confined disease and in approximately 70% even when the primary tumor is abdominal. Generalized loss of lamina dura across multiple teeth—including those distant from the epicenter—is a distinctive feature that should raise suspicion for a hematologic malignancy.[13]
• Tooth displacement and migration: Developing tooth buds may be displaced or their crypts destroyed; erupted teeth become mobile and may appear to "float" within the radiolucency.[8][14]
• Root resorption: External root resorption of involved teeth has been described, though it may be less prominent than the degree of surrounding bone destruction.[9][15]
• Widening of the periodontal ligament space may be an early finding before frank bone destruction is apparent.

Cortical Involvement and Extent

• Cortical destruction is common and may be extensive, with perforation of buccal and lingual cortices.[8][11]
• Extension into the maxillary sinus, nasal cavity, or orbit occurs with maxillary lesions.[6]
• Mandibular lesions may extend to involve the inferior border, ramus, or condylar region.
• Periosteal reaction is generally absent or minimal, distinguishing the pattern from osteomyelitis or Ewing sarcoma.

Growth Pattern

• The permeative destruction pattern reflects the extremely rapid proliferation rate. Serial radiographs taken only 2–3 weeks apart may demonstrate clearly visible progression of bone loss.[9]
• Soft tissue extension is common, producing an associated extraosseous mass that may be disproportionately large relative to the bony defect.

Variants and Special Patterns

• In young children with developing dentition, destruction of tooth crypts and displacement of unerupted tooth germs is characteristic.[8]
• Multifocal jaw involvement (multiple separate radiolucencies) may occur, particularly in the endemic variant.
• CBCT may better delineate the extent of cortical destruction, the relationship of the lesion to the inferior alveolar canal, and early cortical perforation that is not apparent on panoramic radiography.[3][16]

CT

Contrast-enhanced CT demonstrates a homogeneous soft tissue mass with associated osteolytic bone destruction, typically without osteoid or cartilaginous matrix formation.[11] The mass enhances mildly to moderately. CT is superior to dental radiography for defining the full extent of bone destruction, soft tissue involvement, and extension into adjacent spaces (infratemporal fossa, orbit, paranasal sinuses).[3][17]

MRI

MRI shows a relatively homogeneous mass that is typically isointense to muscle on T1-weighted sequences and intermediate-to-high signal on T2-weighted sequences, with mild-to-moderate contrast enhancement.[11] MRI is preferred for evaluating bone marrow infiltration, skull base extension, perineural spread along the inferior alveolar or infraorbital nerves, and orbital or intracranial involvement.[17]

PET/CT

FDG-PET/CT is the preferred staging modality and demonstrates intensely FDG-avid disease (mean SUVmax approximately 14–16 for extranodal lesions).[18] PET/CT is essential for detecting multifocal disease, assessing treatment response, and identifying residual or recurrent disease.[4][19] Pretreatment PET/CT is recommended by NCCN guidelines, though therapy initiation should not be delayed for imaging.[4]

Jaw lesions of Burkitt lymphoma must be distinguished from other aggressive osteolytic processes, particularly in children and young adults. The combination of rapid clinical progression, generalized loss of lamina dura, and permeative bone destruction without matrix production narrows the differential.

The highest-risk diagnostic pitfall is misidentification as odontogenic infection, which delays diagnosis of this rapidly fatal but curable malignancy. Any poorly defined osteolytic jaw lesion with unexplained tooth mobility, neurosensory disturbance, or failure to respond to dental treatment warrants urgent incisional biopsy.[2][3]

Morphology

Biopsy reveals diffuse sheets of monomorphic, medium-sized lymphoid cells with round nuclei, finely dispersed chromatin, multiple small basophilic nucleoli, and deeply basophilic cytoplasm that may contain lipid vacuoles.[1][5] Mitotic figures and apoptotic bodies are numerous. Scattered tingible-body macrophages engulfing apoptotic debris produce the characteristic "starry sky" pattern, though this finding is not pathognomonic and may be absent in some cases.[5] Coagulative necrosis is common; reactive small lymphocytes are rare.[5]

Immunophenotype

• Positive: CD20, CD19, CD10, BCL6, CD38, surface IgM (with light-chain restriction)
• Negative or weak: BCL2 (absent or weak/patchy in ~80% of cases), CD5, TdT
• Ki-67 proliferative index ≥95% (a defining feature)[4][5]

Molecular Features

• The hallmark is MYC rearrangement: t(8;14) in 70–80%, t(2;8) in ~15%, and t(8;22) in ~5% of cases.[1]
• The karyotype is characteristically simple (≤3 clonal aberrations including the 8q24 breakpoint), distinguishing Burkitt lymphoma from high-grade B-cell lymphoma, NOS, which typically has a complex karyotype.[5]
• BCL2 rearrangements are absent; their presence excludes Burkitt lymphoma and indicates high-grade B-cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma).[1][5]
• Recurrent mutations in TCF3/ID3 (40–70%), CCND3, TP53, and CDKN2A contribute to pathogenesis.[19]

Radiologic-Pathologic Correlation

The permeative osteolytic pattern on imaging corresponds to diffuse marrow infiltration by sheets of rapidly proliferating lymphoid cells that destroy trabecular and cortical bone without inducing a reactive osteoblastic or periosteal response. The extremely high proliferation rate (Ki-67 ≥95%) accounts for the rapid radiographic progression documented on serial imaging.[9]

Workup and Referral

Jaw lesions suspicious for Burkitt lymphoma require urgent incisional or core-needle biopsy (fine-needle aspiration is insufficient) with tissue submitted for histopathology, immunohistochemistry, flow cytometry, and FISH.[4] Surgical debulking and tumor resection should be avoided, as recovery delays systemic therapy.[1] Immediate referral to a hematology-oncology center with expertise in aggressive lymphomas is essential.[4]

Staging workup includes PET/CT (preferred) or contrast-enhanced CT of chest/abdomen/pelvis, lumbar puncture with CSF flow cytometry, bone marrow biopsy, CBC, LDH, uric acid, comprehensive metabolic panel, and HIV/hepatitis B testing.[4]

Treatment

• Systemic immunochemotherapy is the definitive treatment. CHOP-based regimens are inadequate.[4]
• High-risk disease (stage III–IV, elevated LDH, or bulky disease): R-CODOX-M/R-IVAC, DA-EPOCH-R for 6 cycles with intrathecal CNS prophylaxis, or HyperCVAD alternating with cytarabine/methotrexate plus rituximab.[4]
• CNS involvement: DA-EPOCH-R alone is not recommended; regimens containing CNS-penetrating agents (high-dose methotrexate, cytarabine) are preferred.[5]
• Rituximab should be included in all regimens.[1][5]
• Tumor lysis syndrome prophylaxis is mandatory.[4]

Prognosis

• Children and adolescents: >90% cure rate with intensive immunochemotherapy.[1]
• Adults: 2-year event-free survival of 65–85% depending on regimen and risk group; DA-EPOCH-R achieves approximately 85% 4-year event-free survival with a favorable toxicity profile.[1]
• Stage is the most significant prognostic variable for jaw-localized disease, with >90% disease-free survival for stage I and >70% for stage II.[8]
• Relapsed or refractory disease carries a very poor prognosis; nearly all such cases are fatal.[1]
• Age ≥40 years is an independent adverse prognostic factor.[20]

Jaw-Specific Outcomes

Complete radiographic resolution of jaw lesions occurs after successful chemotherapy, with restoration of normal bone architecture.[8] No jaw-specific surgical intervention is required for the primary tumor.

EBV Association and Variant Subtyping

The WHO-HAEM5 classification retains the three epidemiologic variants, but emerging evidence suggests that subtyping into EBV-positive and EBV-negative Burkitt lymphoma may better capture biologic heterogeneity.[21][22] EBER-ISH should be performed in endemic settings and immunocompromised patients.[4]

Pediatric Considerations

Jaw involvement in children—particularly bilateral or multiquadrant disease with displacement of developing tooth buds—should prompt immediate consideration of Burkitt lymphoma.[8] Pediatric cases are treated with intensive protocols (e.g., R-BFM) and have excellent outcomes.[20] Ultrasonography or MRI may be substituted for CT in children to minimize radiation exposure.[1]

HIV-Associated Disease

HIV-positive patients with jaw involvement should be treated with the same immunochemotherapy regimens as HIV-negative patients, combined with antiretroviral therapy and prophylaxis for opportunistic infections.[4][5]